Article

BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in Systemic Lupus Erythematosus

2021-07-08

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Objectives</h4> Our aims were to evaluate Systemic Lupus Erythematosus (SLE) disease activity and SARS-CoV-2 specific immune responses after BNT162b2 vaccination. <h4>Methods</h4> In this prospective study, disease activity and clinical assessments were recorded from the first dose of vaccine, until day 15 after the second dose in 126 SLE patients. SARS-CoV-2 antibody responses were measured...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 978bff87-4458-5064-b604-f4732da3704d
DOI: 10.1101/2021.07.07.21260124

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in Systemic Lupus ErythematosusDOI 10.1101/2021.07.07.21260124Read

Reduced response to SARS-CoV-2 vaccination is associated with impaired immunoglobulin class switch recombination in SLE patientsSemantic proximity Read

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and rheumatoid arthritis patientsSemantic proximity Read

Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised PatientsSemantic proximity Read

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity Read

Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity Read

Newly Diagnosed Systemic Lupus Erythematosus after Sars-Cov-2 Vaccination: Coincidental or Relevant?Semantic proximity Read

Cellular and Humoral Responses to SARS-CoV-2 Vaccination in Immunosuppressed PatientsSemantic proximity Read

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialSemantic proximity Read

Immunogenicity and Safety of the Booster BNT162b2 Vaccine in Patients with Axial Spondyloarthritis Treated with Biological Disease-Modifying DrugsSemantic proximity Read

Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Immunocompromised Adults in Greece: Necessity of a Fourth DoseSemantic proximity Read

The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responsesSemantic proximity Read

Impaired Immunogenicity to COVID-19 Vaccines in Autoimmune Systemic Diseases - High Prevalence of Non-Response in Different Patients’ SubgroupsSemantic proximity Read